LIVN - LivaNova: Focus Is Paying Off
2024-05-12 09:46:02 ET
Summary
- LivaNova has streamlined operations and increased income by shutting down ANTHEM trials and releasing new, premium products.
- Operating margins have improved from 10% to 18% due to savings in R&D and the mix effects from Essenz.
- LIVN's epilepsy products are scaling, with new implants driving growth and a strong recurring revenue base.
- Capacity expansions are coming for oxygenators which will increase cardiopulmonary segment volumes starting next quarter.
- Remaining trials are promising yet are being given an implied negative options value, a testament to the existing businesses and also to the value case.
...
LivaNova: Focus Is Paying Off